Thad Wolfram is the Chief Strategy Officer. Mr. Wolfram joined PCM Trials through its acquisition of EmVenio Research in early 2024, bringing over two decades of expertise in clinical trials, healthcare, and the pharmaceutical industry . In his previous role as President at EmVenio Research, he focused on the growth of hybrid and decentralized trial capabilities and increased clinical trial diversity inclusion, improving the health and lives of patients. Before joining EmVenio, Mr. Wolfram served as Executive Director of Corporate Strategy and Development at PPD, leading several initiatives focused on disruption and the future of clinical trials. He also held various senior leadership positions in consulting centered on science and research at EY and PA Consulting Group. Mr. Wolfram earned his MBA in Innovation and Strategic Management from Rensselaer Polytechnic Institute – The Lally School of Management, an MS in Industrial Microbiology / Medical Microbiology from Michigan State University, and a BS in Microbiology and Molecular Genetics from Michigan State University.
